CASB7439 constructs
The present disclosure relates to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, and for methods of utilizing the same.
1. A protein construct comprising a modified CASB7439 polypeptide selected from the group consisting of:
(a) LVL055 (SEQ ID NO:1);
(b) LVL111 (SEQ ID NO:3);
(c) LVL137 (SEQ ID NO:5);
(d) LVL141 (SEQ ID NO:7);
(e) LVL144 (SEQ ID NO:9); and
(f) LVL168 (SEQ ID NO:11).
2. An immunogenic composition comprising the protein construct of claim 1 , and a pharmaceutically acceptable carrier or excipient.
3. The immunogenic composition of claim 2 , wherein the carrier or excipient comprises a buffer.
4. The immunogenic composition of claim 3 , further comprising an adjuvant.
5. The immunogenic composition of claim 4 , wherein the adjuvant comprises a composition selected from the group consisting of: a TLR-4 agonist, an immunologically active saponin fraction, and a TLR-9 agonist.
6. The immunogenic composition of claim 5 wherein said TLR-4 agonist is 3D-MPL.
7. The immunogenic composition of claim 5 wherein said TLR-9 agonist is a CpG oligonucleotide.
8. The immunogenic composition of claim 5 wherein said immunologically active saponin fraction is QS21.
9. The immunogenic composition of claim 5 , further comprising cholesterol.
10. An immunogenic composition which comprises a protein comprising a polypeptide selected from the group consisting of:
(a) the construct set forth in SEQ ID NO:9; and
(b) the construct set forth in SEQ ID NO:11;
and an adjuvant comprising 3DMPL, QS21 in a liposomal formulation, and CpG.
11. A process for producing the immunogenic composition of claim 10 comprising combining a protein comprising a polypeptide selected from the group consisting of:
(a) the construct set forth in SEQ ID NO:9; and
(b) the construct set forth in SEQ ID NO:11;
with 3DMPL, QS21 in a liposomal formulation, and CpG.
12. A nucleic acid molecule comprising a polynucleotide sequence that encodes the protein construct of claim 1 .
13. A method of inducing an immune response to CASB7439 in a human or non-human animal comprising administering to the human or non-human animal an effective amount of a composition comprising an adjuvant and a protein comprising a polypeptide sequence selected from the group consisting of:
(a) the polypeptide sequence set forth in SEQ ID NO:9; and
(b) the polypeptide sequence set forth in SEQ ID NO:11.
14. The method of claim 13 , wherein the animal is human.
15. A method of treating a human or non-human animal comprising the steps of:
(a) selecting a human or non-human animal having cancerous cells that express CASB7439; and
(b) administering to the human or non-human animal an effective amount of a composition comprising an adjuvant and a protein comprising a polypeptide selected from the group consisting of:
(i) the construct set forth in SEQ ID NO:9; and
(ii) the construct set forth in SEQ ID NO:11.
16. The method of claim 15 , wherein the animal is human.